BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35972810)

  • 1. Trametinib as a promising therapeutic option in alleviating vascular defects in an endothelial KRAS-induced mouse model.
    Nguyen HL; Boon LM; Vikkula M
    Hum Mol Genet; 2023 Jan; 32(2):276-289. PubMed ID: 35972810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling.
    Fish JE; Flores Suarez CP; Boudreau E; Herman AM; Gutierrez MC; Gustafson D; DiStefano PV; Cui M; Chen Z; De Ruiz KB; Schexnayder TS; Ward CS; Radovanovic I; Wythe JD
    Circ Res; 2020 Aug; 127(6):727-743. PubMed ID: 32552404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
    Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
    Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal miR-3131 derived from endothelial cells with KRAS mutation promotes EndMT by targeting PICK1 in brain arteriovenous malformations.
    He Q; Huo R; Wang J; Xu H; Zhao S; Zhang J; Sun Y; Jiao Y; Weng J; Zhao J; Cao Y
    CNS Neurosci Ther; 2023 May; 29(5):1312-1324. PubMed ID: 36718590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutation-induced EndMT of brain arteriovenous malformation is mediated through the TGF-β/BMP-SMAD4 pathway.
    Xu H; Huo R; Li H; Jiao Y; Weng J; Wang J; Yan Z; Zhang J; Zhao S; He Q; Sun Y; Wang S; Cao Y
    Stroke Vasc Neurol; 2023 Jun; 8(3):197-206. PubMed ID: 36418055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS G12D or G12V Mutation in Human Brain Arteriovenous Malformations.
    Oka M; Kushamae M; Aoki T; Yamaguchi T; Kitazato K; Abekura Y; Kawamata T; Mizutani T; Miyamoto S; Takagi Y
    World Neurosurg; 2019 Jun; 126():e1365-e1373. PubMed ID: 30902772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mouse models for human colorectal cancer with liver metastasis].
    Huang XD; Zheng YB; Yang YJ; Yang C; Li HL; Cheng HR
    Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(34):2701-2705. PubMed ID: 31505723
    [No Abstract]   [Full Text] [Related]  

  • 10. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
    Hu X; Zhang R; Yao J; Mu B; Zhao C
    Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36367161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model.
    Ray KC; Bell KM; Yan J; Gu G; Chung CH; Washington MK; Means AL
    PLoS One; 2011 Feb; 6(2):e16786. PubMed ID: 21311774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of thymic tumor in [LSL:Kras
    Liot S; El Kholti N; Balas J; Genestier L; Verrier B; Valcourt U; Lambert E
    Sci Rep; 2021 Jul; 11(1):15075. PubMed ID: 34302028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice.
    Park ES; Kim S; Huang S; Yoo JY; Körbelin J; Lee TJ; Kaur B; Dash PK; Chen PR; Kim E
    Ann Neurol; 2021 May; 89(5):926-941. PubMed ID: 33675084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kras
    Cheng H; Fan K; Luo G; Fan Z; Yang C; Huang Q; Jin K; Xu J; Yu X; Liu C
    Cancer Lett; 2019 Apr; 446():103-111. PubMed ID: 30664964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS
    Zhou C; Fan Z; Gu Y; Ge Z; Tao Z; Cui R; Li Y; Zhou G; Huo R; Gao M; Wang D; He W; Zheng M; Zhang S; Xu T
    J Med Chem; 2024 Jan; 67(2):1147-1167. PubMed ID: 38197882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.